Loading...
•
Jun 30, 2023
CRISPR Therapeutics Q2 2023 Earnings Report
CRISPR Therapeutics reported financial results and business updates for Q2 2023.
Key Takeaways
CRISPR Therapeutics reported a net loss of $77.7 million for the second quarter of 2023, with total collaboration revenue of $70.0 million. The FDA accepted BLAs for exa-cel for severe SCD and TDT, marking significant progress towards delivering innovative gene-edited therapies.
FDA accepted Biologics License Applications (BLAs) for exagamglogene autotemcel (exa-cel) for severe Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT).
Enrollment and dosing are ongoing for CTX110 targeting CD19+ B-cell malignancies and CTX130 targeting CD70 for the treatment of T cell lymphomas.
Enrollment is ongoing and dosing initiated for next-generation CAR T candidates, CTX112 targeting CD19+ B-cell malignancies and CTX131 targeting CD70+ solid tumors.
A Phase 1/2 clinical trial of VCTX211 for the treatment of Type 1 Diabetes (T1D) continues with enrollment and dosing ongoing.
CRISPR Therapeutics
CRISPR Therapeutics
CRISPR Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
CRISPR Therapeutics is advancing multiple clinical programs and expects to initiate a clinical trial for CTX310 this year, with plans to enter the clinic with an investigational program targeting lipoprotein (a) (Lp(a)) in the first half of 2024.
Positive Outlook
- Advancing lead in vivo program, CTX310, targeting ANGPTL3, into the clinic this year.
- Progressing an investigational program targeting lipoprotein (a) (Lp(a)) and expects to enter the clinic in the first half of 2024.
- Continuing enrollment and dosing in a Phase 2 single-arm potentially registrational clinical trial of CTX110.
- Continuing enrollment and dosing in the Phase 1 COBALT-LYM trial evaluating the safety and efficacy of CTX130.
- Continuing to enroll and has initiated dosing in a Phase 1 clinical trial of CTX112.